The artificial pancreas aims to automate blood sugar control for people with Type 1 diabetes.
Research and publish the best content.
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Already have an account: Login
Bioscience News - GEG Tech top picks
8.8K views |
+0 today
 Your new post is loading...
Your new post is loading...
Scoop.it!
When certain bacteria are found in a patient's mouth, it may indicate an increased risk for pancreatic cancer, according to a study presented by U.S. researchers at the meeting of the American Association for Cancer Research
BigField GEG Tech's insight:
When certain bacteria are found in a patient's mouth, it may indicate an increased risk for pancreatic cancer, according to a study presented by U.S. researchers at the meeting of the American Association for Cancer Research 
|
Scoop.it!
BigField GEG Tech's insight:
FDA-approved artemisinins, which have been used for decades to treat malaria, transform glucagon-producing alpha cells in the pancreas into insulin producing cells, researchers report.
Scoop.it!
BigField GEG Tech's insight:
To investigate the roles and therapeutic potential for targeting the RORs in type 1 diabetes, the scientists administered SR1001, a selective RORα/γ inverse agonist, to non-obese diabetic (NOD) mice. SR1001 significantly reduced diabetes incidence and insulitis in treated mice. Furthermore, SR1001 reduced pro-inflammatory cytokine expression, particularly TH17-mediated cytokines, reduced autoantibody production, and increased the frequency of CD4+Foxp3+ T regulatory cells.
|
A pilot study among young children with Type 1 diabetes found that a University of Virginia-developed artificial pancreas helped study participants better control their condition.